The inhibition effect and mechanism of SY0916 on pulmonary fibrosis.

J Asian Nat Prod Res

a Department of Pharmacology , Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050 , China.

Published: September 2014

SY0916 is a new platelet-activating factor receptor antagonist developed by our institute. In this study, the inhibitory effect of SY0916 on pulmonary fibrosis was investigated in epithelial-mesenchymal transition (EMT) induced by transforming growth factor beta 1 (TGF-β1) in vitro and a pulmonary fibrosis animal model induced by bleomycin (BLM). The results showed that SY0916 could inhibit the EMT of A549 cells induced with TGF-β1. In vivo, SY0916 administration significantly ameliorated the BLM-mediated histological changes, reduced main biochemical parameters related to pulmonary fibrosis such as hydroxyproline and glutathione, and also notably attenuated the expression of key pro-fibrotic mediator, TGF-β1. These findings demonstrated that SY0916 could possibly be developed as a promising candidate for the treatment of pulmonary fibrosis.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10286020.2014.917629DOI Listing

Publication Analysis

Top Keywords

pulmonary fibrosis
20
sy0916 pulmonary
8
sy0916
6
pulmonary
5
fibrosis
5
inhibition mechanism
4
mechanism sy0916
4
fibrosis sy0916
4
sy0916 platelet-activating
4
platelet-activating factor
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!